Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

 Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration of Neutropenia

Shots:

  • The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis
  • The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety, efficacy, PK, immunogenicity in patients with moderate to severe chronic plaque-type psoriasis
  • Hyrimoz (adalimumab) is an inhibitor of tumor necrosis factor (TNF) indicated for rheumatoid arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis-causing inflammation and tissue destruction

Click here read full press release/ article | Ref: Sandoz | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post